GLP-1 Drugs List 2026: Every FDA-Approved GLP-1 Medication and What Each Is Used For
Nine brand-name products built on five active ingredients-exenatide, liraglutide, dulaglutide, semaglutide, and tirzepatide-now make up the U.S. arsenal of GLP-1 and dual GIP/GLP-1 therapies approved for diabetes or chronic weight management.
As of October 2026, the U.S. Food and Drug Administration (FDA) has cleared nine prescription products that work through the glucagon-like peptide-1 (GLP-1) pathway-including one dual GIP/GLP-1 agent-for treating type 2 diabetes, reducing cardiovascular risk, or promoting chronic weight loss. Knowing which brand contains which active ingredient, whether it is an injectable or a pill, and what each is officially approved to do helps patients and clinicians pick the safest, most effective option.
- The first GLP-1 receptor agonist, exenatide injection (Byetta), was approved in 2005 for type 2 diabetes.
- Semaglutide appears in three brands: once-weekly Ozempic (2017, diabetes), daily oral Rybelsus (2019, diabetes), and once-weekly Wegovy (2021, obesity).
- The dual GIP/GLP-1 drug tirzepatide powers Mounjaro (2022, diabetes) and Zepbound (2023, obesity).
- Liraglutide lowered cardiovascular and total mortality in the LEADER trial, leading the FDA to add heart-protection language to Victoza’s label in 2017 fda.gov.
- In a 2025 Japanese hospital review, 23.4% of adults aged 65 and older receiving glucose-lowering therapy were prescribed a GLP-1 agent (Sato et al., 2026).
- You can compare cash prices on all nine brands at your local pharmacies with a free Rx.com prescription discount card.
What GLP-1 Drugs Are and How They Work
GLP-1 medications mimic or enhance the effects of glucagon-like peptide-1, a natural gut hormone that stimulates insulin, suppresses glucagon, slows stomach emptying, and reduces appetite. By improving glucose control and promoting weight loss, they lower the risk of diabetes complications and, for some agents, major cardiovascular events (Madsbad, 2019).
Mechanism of action: The drugs bind to GLP-1 receptors on pancreatic beta cells, boosting meal-dependent insulin release while limiting glucagon when glucose is high. Slower gastric emptying and central appetite signaling translate to fewer calories consumed, which supports sustained weight reduction.
Complete FDA-Approved GLP-1 Drug List
Nine branded products using five active ingredients are FDA-approved as of 2026. The table below summarizes each one.
| Brand (Year) | Active Ingredient | Manufacturer | Form | First FDA Approval |
|---|---|---|---|---|
| Byetta (2005) | Exenatide | AstraZeneca | Twice-daily injection | Type 2 diabetes |
| Bydureon BCise (2012) | Exenatide ER | AstraZeneca | Once-weekly injection | Type 2 diabetes |
| Victoza (2010) | Liraglutide | Novo Nordisk | Once-daily injection | Type 2 diabetes |
| Saxenda (2014) | Liraglutide | Novo Nordisk | Once-daily injection | Chronic weight management |
| Trulicity (2014) | Dulaglutide | Eli Lilly | Once-weekly injection | Type 2 diabetes |
| Ozempic (2017) | Semaglutide | Novo Nordisk | Once-weekly injection | Type 2 diabetes |
| Rybelsus (2019) | Semaglutide | Novo Nordisk | Once-daily oral tablet | Type 2 diabetes |
| Wegovy (2021) | Semaglutide | Novo Nordisk | Once-weekly injection | Chronic weight management |
| Mounjaro (2022) | Tirzepatide (GIP/GLP-1) | Eli Lilly | Once-weekly injection | Type 2 diabetes |
| Zepbound (2023) | Tirzepatide (GIP/GLP-1) | Eli Lilly | Once-weekly injection | Chronic weight management |
Who Each Drug Is Approved to Treat
The official indication matters: some brands target blood sugar, others target weight loss, and several carry cardiovascular or pediatric extensions.
| Brand | Main FDA-Approved Uses | Age Range |
|---|---|---|
| Byetta / Bydureon | Add-on therapy to diet and exercise for adults with type 2 diabetes | 18 years + |
| Victoza | Type 2 diabetes in adults and children 10 years +, to reduce cardiovascular death in adults with established disease | 10 years + |
| Saxenda | Chronic weight management in adults with BMI ≥ 30 or BMI ≥ 27 with a weight-related condition | 12 years + |
| Trulicity | Type 2 diabetes; to reduce major cardiovascular events in adults with both diabetes and heart disease | 10 years + |
| Ozempic | Type 2 diabetes; to reduce cardiovascular events in adults with diabetes and known heart disease | 18 years + |
| Rybelsus | Oral treatment of type 2 diabetes as first-line or add-on | 18 years + |
| Wegovy | Long-term weight management in adults and adolescents with obesity | 12 years + |
| Mounjaro | Improve glycemic control in type 2 diabetes | 18 years + |
| Zepbound | Chronic weight management in adults with obesity or overweight plus one comorbidity | 18 years + |
How to Choose the Right GLP-1 Agent
Decision-making should balance the indication (diabetes, weight, or both), dosing convenience, tolerability, and insurance coverage. Below are key factors to discuss with your prescriber.
Dosing frequency: Once-weekly injections such as Ozempic, Trulicity, Mounjaro, Wegovy, and Zepbound fit best for people who dislike daily shots. Rybelsus offers the first oral option but must be taken on an empty stomach with water only.
Heart and kidney protection: Liraglutide showed a 13% relative reduction in the composite of cardiovascular death, non-fatal heart attack, or non-fatal stroke in LEADER (Madsbad, 2019). Semaglutide has similar label language based on the SUSTAIN-6 trial (fda.gov). If you already have heart disease, those brands may take priority.
Weight-loss potency: In clinical trials, weekly semaglutide 2.4 mg (Wegovy) produced an average 15% body-weight reduction, while weekly tirzepatide 15 mg (Zepbound) averaged about 20% (fda.gov). Discuss realistic goals with your provider.
Tolerability: Nausea and diarrhea are the most common side effects across the class; slower dose escalation helps. Older adults often take multiple medications; in one Japanese review, GLP-1 users averaged 3.2 concomitant glucose-lowering drugs, underscoring the need to review interactions (Sato et al., 2026).
Cost and access: List prices exceed $900 per month for many brands. Manufacturer savings cards can cut insured copays, but coverage rules vary. The free Rx.com discount card lets you check real-time pharmacy cash prices and may beat insurance at some chains.
How to Save on Brand-Name GLP-1 Therapy
Combining insurance, manufacturer programs, and pricing tools often yields the lowest out-of-pocket cost.
Manufacturer savings cards: Novo Nordisk’s Ozempic card can lower copays to as little as $25 for eligible insured adults; Wegovy’s card caps monthly cost at $0 for some plans but has dollar limits (fda.gov). Lilly’s Mounjaro and Zepbound cards offer similar commercial insurance savings.
Medicare and Medicaid: Coverage depends on the plan’s formulary. Many Medicare Part D plans cover Ozempic and Trulicity for diabetes but exclude Wegovy and Zepbound. Some state Medicaid programs now cover at least one weight-loss GLP-1.
Cash-price shopping: Use the Rx.com discount card to compare local pharmacy prices. Prices can vary by more than $100 between chains.
Telehealth programs: If insurance denies a brand, some patients consider compounded alternatives. Compounded GLP-1 products are prepared by 503A pharmacies for individual patients, are not FDA-approved, and are not the same as any brand-name medication. Compare any quoted price with Rx.com’s compounded semaglutide from $99 per month and tirzepatide from $149 per month on a 12-month plan at the Rx.com weight loss program page.
Is a GLP-1 the right next step for you?
Check the column that fits your situation:
✅ Likely a good fit
- Type 2 diabetes not at goal despite metformin
- BMI ≥ 30 (or ≥ 27 with a related condition)
- No personal or family history of medullary thyroid cancer
- Willing to inject weekly or follow strict oral tablet rules
🏥 See a doctor first
- Type 1 diabetes or diabetic ketoacidosis history
- Severe gastrointestinal disease such as gastroparesis
- Pregnant, planning pregnancy, or breastfeeding
- Pancreatitis or gallstones within the past year
- eGFR < 15 mL/min with dialysis
- Multiple daily episodes of unexplained hypoglycemia
When to Contact Your Doctor
🚨 When to Contact Your Healthcare Provider
Call your prescriber right away if you notice any of the following while taking a GLP-1 or GIP/GLP-1 medicine:
- Severe, persistent stomach pain: could signal pancreatitis.
- Repeated vomiting or inability to keep liquids down: risk of dehydration.
- Yellowing of skin or eyes: possible gallbladder or liver issues.
- Swelling of the neck or trouble swallowing: report any thyroid nodules.
- Signs of hypoglycemia such as confusion or fainting, especially if on insulin.
- Shortness of breath, swelling in legs, or rapid weight gain: may indicate heart failure.
- Changes in vision: sudden blurring can follow rapid glucose improvement.
- Thoughts of self-harm; if you feel unsafe, call or text 988 (Suicide & Crisis Lifeline) 24/7.
Scientific References
- Sato M, Takemura R, Yuki M, et al. Prescribing of GLP-1 and GIP/GLP-1 Receptor Agonists and Other Glucose-Lowering Drugs Requiring Special Caution in Elderly Japanese People With Type 2 Diabetes: A Preliminary Report. J Clin Med Res. 2026.
- Madsbad S. Liraglutide for the prevention of major adverse cardiovascular events in diabetic patients. Expert Rev Cardiovasc Ther. 2019.
- U.S. Food and Drug Administration. fda.gov.
Frequently Asked Questions
What is the difference between GLP-1 and GIP/GLP-1 drugs?
Traditional agents such as Ozempic act only on the GLP-1 receptor, while tirzepatide (Mounjaro, Zepbound) also targets the glucose-dependent insulinotropic polypeptide (GIP) receptor. Early data suggest the added GIP action enhances weight and glucose effects, though side-effect profiles overlap.
Which GLP-1 pill is FDA-approved?
Rybelsus is the only oral GLP-1 agent approved in the United States. It contains semaglutide in a special absorption enhancer and must be taken first thing in the morning with no more than 4 ounces of water, at least 30 minutes before food.
Can I switch from Ozempic to Wegovy?
Yes, both contain semaglutide but have different dose strengths and indications. Your provider will assess timing, starting dose, and insurance coverage. Never change pens without medical guidance.
Are GLP-1 drugs safe for people over 65?
GLP-1 agents work in older adults, but caution is warranted because polypharmacy and kidney impairment are common. In one study of Japanese seniors, 23.4% of treated patients received a GLP-1, often alongside other cautious-use drugs (Sato et al., 2026). Dose adjustments may be needed if kidney function declines.
Do any GLP-1 medications have generic versions?
No. All FDA-approved GLP-1 and GIP/GLP-1 products are protected by patents. Compounded versions prepared by pharmacies are not FDA-approved generics and are legally different from the brands.
How long do I need to stay on a GLP-1 for weight loss?
Long-term use is generally required to maintain weight reduction. Stopping treatment often leads to partial regain. Your clinician will monitor benefits and side effects to decide duration.
Can I use a GLP-1 if I have type 1 diabetes?
No. GLP-1 receptor agonists and tirzepatide are not approved for type 1 diabetes and can increase the risk of diabetic ketoacidosis in insulin-dependent patients.
What diet should I follow while on a GLP-1 drug?
Most providers recommend a balanced, calorie-reduced diet rich in lean protein, vegetables, whole grains, and adequate hydration. Large high-fat meals can worsen nausea.
